BR0008788A - Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase - Google Patents

Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase

Info

Publication number
BR0008788A
BR0008788A BR0008788-2A BR0008788A BR0008788A BR 0008788 A BR0008788 A BR 0008788A BR 0008788 A BR0008788 A BR 0008788A BR 0008788 A BR0008788 A BR 0008788A
Authority
BR
Brazil
Prior art keywords
components
directed against
tumor
ribonucleotide reductase
sequences directed
Prior art date
Application number
BR0008788-2A
Other languages
English (en)
Inventor
Jim A Wright
Aiping H Young
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Publication of BR0008788A publication Critical patent/BR0008788A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "SEQuêNCIAS ANTI-SENTIDO ANTITUMOR DIRIGIDAS CONTRA COMPONENTES R1 E R2 DE RIBONUCLEOTìDEO REDUCTASE". Compostos e métodos para modular a proliferação celular, preferivelmente inibir a proliferação de células de tumor são descritos. Os compostos que podem ser usados para modular a proliferação celular incluem oligonucleotídeos anti-sentido complementares a regiões dos genes ribonucleotídeo reductase de mamíferos.
BR0008788-2A 1999-02-11 2000-02-09 Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase BR0008788A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/249,730 US6121000A (en) 1999-02-11 1999-02-11 Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
PCT/CA2000/000120 WO2000047733A1 (en) 1999-02-11 2000-02-09 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Publications (1)

Publication Number Publication Date
BR0008788A true BR0008788A (pt) 2001-11-06

Family

ID=22944744

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008788-2A BR0008788A (pt) 1999-02-11 2000-02-09 Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase

Country Status (17)

Country Link
US (1) US6121000A (pt)
EP (1) EP1153128B8 (pt)
JP (1) JP4424857B2 (pt)
KR (1) KR20020013501A (pt)
CN (1) CN1345373A (pt)
AR (1) AR022583A1 (pt)
AT (1) ATE309346T1 (pt)
AU (1) AU780455B2 (pt)
BR (1) BR0008788A (pt)
CA (1) CA2366487A1 (pt)
DE (1) DE60023845T2 (pt)
ES (1) ES2259602T3 (pt)
IL (1) IL144727A0 (pt)
MX (1) MXPA01008137A (pt)
NZ (1) NZ514090A (pt)
RU (1) RU2001124840A (pt)
WO (1) WO2000047733A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593305B1 (en) * 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
ES2397060T3 (es) * 2002-04-18 2013-03-04 Opko Pharmaceuticals, Llc Medios y métodos para la modulación específica de genes diana en el ojo
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004070033A1 (en) 2003-02-10 2004-08-19 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
WO2004094606A2 (en) * 2003-04-18 2004-11-04 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2
CN1302936C (zh) * 2003-05-02 2007-03-07 精工爱普生株式会社 打印机
US20070274947A1 (en) * 2003-05-21 2007-11-29 Young Aiping H Antisense Oligonucleotides Directed to Ribonucleotide Reductase R1 and Uses Thereof in the Treatment of Cancer
WO2004106518A1 (en) * 2003-05-31 2004-12-09 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US20080311126A1 (en) * 2004-01-12 2008-12-18 Genesense Technologies, Inc Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer
US8029815B2 (en) * 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
EP1786905B1 (en) * 2004-08-18 2011-08-03 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
WO2007133758A1 (en) * 2006-05-15 2007-11-22 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
US20080152654A1 (en) * 2006-06-12 2008-06-26 Exegenics, Inc., D/B/A Opko Health, Inc. COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
US9526707B2 (en) * 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US8470792B2 (en) 2008-12-04 2013-06-25 Opko Pharmaceuticals, Llc. Compositions and methods for selective inhibition of VEGF
DE102019000490A1 (de) * 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5766855A (en) * 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0690869A1 (en) * 1993-03-23 1996-01-10 The Board Of Trustees Of The Leland Stanford Junior University Cellular regulation with riboregulators
ES2256893T3 (es) * 1996-08-02 2006-07-16 Genesense Technologies Inc. Secuencias antisentido antitumorales dirigidas contra componentes r1 y r2 de la reductasa ribonucleica.

Also Published As

Publication number Publication date
WO2000047733A9 (en) 2001-03-15
EP1153128B1 (en) 2005-11-09
AU780455B2 (en) 2005-03-24
ES2259602T3 (es) 2006-10-16
WO2000047733A1 (en) 2000-08-17
RU2001124840A (ru) 2004-03-27
NZ514090A (en) 2005-01-28
EP1153128A1 (en) 2001-11-14
IL144727A0 (en) 2002-06-30
KR20020013501A (ko) 2002-02-20
CA2366487A1 (en) 2000-08-17
AR022583A1 (es) 2002-09-04
DE60023845D1 (de) 2005-12-15
US6121000A (en) 2000-09-19
AU2529200A (en) 2000-08-29
MXPA01008137A (es) 2004-08-12
ATE309346T1 (de) 2005-11-15
JP4424857B2 (ja) 2010-03-03
EP1153128B8 (en) 2006-01-18
CN1345373A (zh) 2002-04-17
DE60023845T2 (de) 2006-08-10
JP2003500006A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
CA2262776A1 (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
EP1507005A3 (en) Antisense modulation of BCL-X expression
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
EP1190099A4 (en) ANTISENSE MODULATION OF THE P13K P85 EXPRESSION
EP1165594A4 (en) MODULATION OF STAT3 EXPRESSION USING ANTISENSE OLIGONUCLEOTIDES
ZA987491B (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
PT1117672E (pt) Modulação anti-sentido da expressão de survivina
EP1131465A4 (en) ANTISENSE MODULATION OF THE INTERLEUKIN-15 EXPRESSION
WO1998000532A3 (en) Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
WO2003048315A3 (en) Antisense modulation of mdm2 expression
EP1135402A4 (en) ANTISENSE MODULATION OF THE EGR-1 EXPRESSION
MY138257A (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
EP1224202A4 (en) ANTISENSE MODULATION OF INTEGRIN MEDIUM KINASE EXPRESSION
EP1165145A4 (en) ANTISENSE REGULATION OF MDMX EXPRESSION
AU2606000A (en) Antisense modulation of x-linked inhibitor of apoptosis expression
EP1173458A4 (en) ANTISENSE MODULATION OF SRA EXPRESSION
DE69938501D1 (de) Verwendung von prohibitin-rns in krebsbehandlung
EP1210454A4 (en) ANTISENSE MODULATION OF SHP-1 EXPRESSION
WO2003049691A3 (en) Antisense modulation of pctaire protein kinase 1 expression

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]